PROBI – FIRST IN PROBIOTICS COMMERCIAL PROFILE
Transcription
PROBI – FIRST IN PROBIOTICS COMMERCIAL PROFILE
PROBI – FIRST IN PROBIOTICS COMMERCIAL PROFILE FIVE REASONS FOR PROBI ROBUST STRAINS FOR STABILITY Product stability and long shelf-life thanks to robust strains proven to PROBIOTICS CREATE BENEFITS FOR YOU AND YOUR CUSTOMERS withstand industrial production and supply chain. The market for probiotics is large and growing rapidly. Probiotics will increase value, sales and margins. There are significant and WELL-DOCUMENTED AND PATENTED PROBIOTIC STRAINS perceived health benefits for your customers, thus creating consumer The foundation of Probi is research and development. Comprehensive loyalty. clinical studies prove the effects of Probi’s potent probiotic bacteria. Probi currently has more than 100 patents worldwide. A PARTNERSHIP MODEL WHERE ALL COMPETENCES ARE UTILIZED TO A MAXIMUM PROBI IS A LEADING PLAYER WITHIN PROBIOTIC RESEARCH AND HAS A LONG HISTORY OF SUCCESSFUL DEVELOPMENT Probi is a leading player in probiotic research and development of Probi has a proven track-record with its long-term partner model that effective and well-documented probiotics. The company was founded benefits both partners. A model which has been developed together in 1991 and has a strong history of successful developments within with partners over more than 15 years. the areas of the gastrointestinal tract, immune system and recovery. Probi’s customers are leading companies in the Functional Food and Consumer Healthcare segments. The company is listed on Nasdaq OMX Stockholm, Small Cap. Probiotics with product-specific health claims WHY PROBIOTICS? The World Health Organization defines probiotics as “live micro-organisms which, when administered in sufficient amounts, confer a health benefit on the host”. Probiotics with generic health claims The composition of the gastrointestinal microflora is very important to our health. Probiotics help to balance the Probiotics with limited documentation intestinal flora, which can result in a healthier digestive system and strong immune system. Elie Metchnikoff (1845-1916) is said to be the father of Bacteria with no documentation 2 PROBI – FIRST IN PROBIOTICS probiotics and was awarded the Nobel Prize in medicine 1908 for his research concerning the human immune system. O U R A D VA N C E S P R O V I D E A S O L I D P L AT F O R M FOR CONTINUED COMMERCIAL DEVELOPMENT Peter Nählstedt, CEO Niklas Brandt, CFO Gun-Britt Fransson, Vice President Research & Development Niklas Bjärum, Vice President Marketing & Sales It is now 20 years since Skånemejerier launched ProViva - a are now available, and the health benefits of macrobiotic foods are revolutionary fruit drink at the time, developed by Probi in partnership gradually being identified. As a result, more sophisticated probiotic with Skånemejerier. The drink demonstrably helped consumers feel products will be developed in the future, as well as other types of better. ProViva proved a significant milestone in our history. products that can influence our microbiota. Our focus on research provides real opportunities for participating in this advancement, and Probi has managed to transform its research results in IBS and immunity we are rigorously monitoring all developments. support into a successful business. Following the initial success with ProViva, we launched an entirely new business area in Consumer CAPACITY FOR CONTINUED ADVANCEMENT Healthcare. In recent years, we have refined our business model We are working tirelessly toward our long-term objective of being to also include establishing our proprietary brand Probi® among a prominent probiotic company, at an international level, and the consumers. capacity to overcome both our long and more short-term challenges is highly favourable. We have consistently demonstrated strong business Our operations are international with agreements covering some 40 results and the many years of research behind our products provide countries. In parallel with this development, our sales have increased strength amid international competition. every year, with retained profitability, despite challenges in the form of a weaker economy and more stringent regulatory requirements The best part of the Probi story is that so much still remains to be done. throughout the industry. We would very much like to discuss these opportunities with you. NEW RESEARCH PRESENTS NEW OPPORTUNITIES Meanwhile, we hope you will enjoy reading this introduction to Probi. The approximately ten quintillion bacteria that colonise every human body, our microbiota, are now one of the most important fields in medical research. Tools for mapping microbiota and their effects PROBI – FIRST IN PROBIOTICS 3 SCIENCE FOR A GOOD LIFE – PROBI IN BRIEF WORLD LEADER AND YOUR PARTNER IN PROBIOTICS VISION Probi operates in the global health-products market. The company Probi’s vision is to be the world leader in the premium segment for offers potent and robust probiotics to food, health and pharmaceutical probiotics by providing a top-quality product range, with profound companies. In turn, these offer their customers probiotics in the form health benefits, in the world’s most important health markets. of functional food under such brands as ProViva , GoodBelly and ® ® Golden Circle Healthy Life™, or dietary supplements under such MISSION proprietary brands as Bion® and Nature Made®. Probi also offers Probi provides consumers the world over with the opportunity to its proprietary brands, Probi Mage and Probi Frisk , in the Nordic improve their health through clinically tested, effective probiotics. ® ® markets. BUSINESS CONCEPT THE PROBIOTIC MARKET IN BRIEF To provide probiotics with well-documented, positive health benefits The global probiotics market is highly heterogeneous, both in terms for leading food and dietary supplement companies. of the types of products and their health effects. In addition, the level of maturity among different markets varies. Probiotics have a STRATEGY strong position in Japan as a result of a long tradition of use and Probi’s strategic focus is on probiotic-based products, where Probi an advanced regulatory system while the North American market is has world-leading, patented technology. Probi’s growth strategy relatively immature but in rapid development. comprises initiatives in the following areas: BUSINESS AREAS • New markets Probi’s business is organised into two business areas, Functional Food Most of Probi’s sales today are still in the Nordic region and the and Consumer Healthcare: potential for international growth is strong. Markets where Probi has most growth potential include Asia, North America and Eastern • Functional Food Europe. In the North American market, Probi will continue to focus on Probi’s Functional Food business area develops food that provides expanding the number of sales channels. beneficial health effects. This takes place in partnership with leading food companies with the aim of commercialising and marketing • New product platforms products with high volume potential. Probi currently has products in the gastrointestinal health and immune fields. The research strategy is to develop additional clinical platforms • Consumer Healthcare and produce products in new indication areas. The Consumer Healthcare business area develops, markets and sells Probi® probiotics in partnership with pharmaceutical companies and • New product formats other companies specialised in probiotics and self-care products, The development strategy in this area focuses on developing new under Probi’s proprietary brand and those of its partners. The regulatory product solutions based on Probi’s existing platforms, Probi Digestis® status of the products is either food or consumer pharmaceuticals and Probi Defendum®. One example could be target-group-adapted depending on the market. combination products with probiotics plus vitamins or minerals. 2004 2002 1991 Probi was founded. Patent application LP299V®, and others. 1986 Cross functional research begins at Lund University. 4 PROBI – FIRST IN PROBIOTICS 1994 1998 Listing on NGM. License agreement: Skånemejerier, ProViva. 2000 Publication of scientific studies in Clinical Nutrition. Publication of positive results on functional disturbances of the intestine (IBS). 2003 Listing on the Stockholm Stock Exchange. Development of products together with Danone och Institut Rosell. Development of nutritional products for health care. License agreement with Danone and Institut Rosell. Patent application dealing with new bacterial strains. LIST OF SELECTED PARTNERS Functional Food: Consumer Healthcare: • Aristo • Danone • BiO-LiFE • H.J. Heinz Australia • Bringwell • Kraft Foods • Ferring • NextFoods • Health World • Jarrow Formulas • Merck • Metagenics • Pharmavite • Proton System • Sanofi • Sanum Polska • USV Ltd. 2006 Agreement with Metagenics in USA. 2005 Institut Roselllaunches the first dietary supplement. 2007 2010 2008 NextFoods launches fruit drinks and Kraft Foods launches müsli bars. Agreement with NextFoods. License and distribution agreement with Kraft Foods. 2009 Launch of supplements under the Probi® brands. Launch of unique Bravo Friscus 100% juice with strong Immune propositions. 2012 Heinz launches immune juice in Australia. Pharmavite launches suppl. in USA. 2011 Danone acquires ProViva and signs Intl. License agreement with Probi. PROBI – FIRST IN PROBIOTICS 5 MARKET AND TRENDS PROBIOTIC MARKET In 2003, the global market for probiotics amounted to approx. USD LIFESTYLE-RELATED DISEASES REACHING EPIDEMIC PROPORTIONS 32.5 million, with the dietary supplement market representing about Lifestyle-related diseases are rising sharply all over the world and one-tenth of the food market.* pose one of the greatest threats to human health and development. These include cardiovascular diseases, cancer, chronic respiratory ROBUST GROWTH IN THE PROBIOTICS MARKET CONTINUES diseases and diabetes, which are responsible for an estimated 35 million deaths annually, or about 60% of all deaths globally. Asia is the largest market. Due to the strong population growth and greater prosperity, demand is expected to increase most in Asia in the One of the primary contributors to this development is an unhealthy years ahead, mainly in China and India. diet. The World Health Organization (WHO) claims that a large proportion of cardiovascular diseases, stroke and type 2 diabetes In percentage terms, the US is the fastest growing market. Annual could be prevented with a healthier diet, which favours sales of sales of probiotic products in the US market have more than doubled probiotic food and drinks. over the past two years. Russia has also grown by between 2530%. Other major markets with favourable growth include Brazil and The global health trend is strong and the awareness of health factors Poland, with annual growth exceeding 5% in recent years. associated with unhealthy diet is rising. Another strong driver is the rising average income, primarily in certain markets in Asia and South Due to the ban on using health claims in the EU, many players have reduced their marketing campaigns in the EU in recent years. Food products such as yoghurt and beverages dominate the probiotic market. The market for both probiotic dietary supplements, which account for about 10% of the food market, and probiotic juices is expected to show favourable growth over the coming years. In general, growth of probiotic dietary supplements is considered higher than that of probiotic food products. *Source: Euromonitor 2014 6 PROBI – FIRST IN PROBIOTICS America. PROVIVA – OUR BIGGEST SUCCESS SO FAR ProViva – building value LITERS ProViva was launched 1994 in a very successful partnership with the regional and progressive dairy company Skånemejerier. Ever 30 000 25 000 since, the brand has shown a very strong annual growth in the Nordics. ProViva was first in many aspects. It was pioneering with Functional Food in the Nordics, which introduced a whole new category of foods, and the technology of adding company probiotics into a fruit drink was unheard of. Since then, Skånemejerier/Danone have launched several new 20 000 15 000 10 000 5 000 10 20 05 20 00 20 19 women, as a sports/recovery drink and as a shot. 95 line extensions - in yoghurt, products specifically designed for Although the brand has not been extensively supported by ProViva has had great success in Sweden with a population of marketing investments, sales growth has been strong and steady. 9 million reaching sales of USD 100 million. Taking the ProViva The basis for ProViva’s excellent development is: concept and introducing it on a larger scale in a pan-European • Consumers find it tasty, convenient and affordable. market or in the US market has untapped potential for Probi. • Consumers percieve the functional gastro benefit shortly Given the same penetration rate, sales could potentially amount to after consumption. several billions of USD. • Extensive and convincing scientific documentation is important to the scientific community and authorities. • Our partners have shown a strong determination in developing the brand and the products. PROBI – FIRST IN PROBIOTICS 7 P R O D U C T P L AT F O R M S Probi’s product platforms Probi Digestis® and Probi Defendum® are based on solid clinical data from a large number of clinical trials. They provide a basis for internationally competitive products that are purchased by consumers because they experience significant improvements in their health. Probi Digestis®: clinical documentation for colon irritabile/IBS (irritable bowel syndrome) based on Lactobacillus plantarum 299v (DSM 9843). Probi Defendum®: clinical documentation for the prevention and relief of colds and similar infections based on a combination of the bacterial strains Lactobacillus plantarum Heal 9 (DSM 15312) and Lactobacillus paracasei 8700:2 (DSM 13434). LARGE MARKET On average 20-25% of the population suffer from IBS CLINICAL EFFECTS Lactobacillus plantarum 299v is one of the world’s most researched probiotic (+40 clinical studies) and has demonstrated the broadest health effects ranging from GI disorders to metabolic effects like reduction of risk factors for cardiovascular disease. Probi has, in a number of state-of-the-art designed clinical studies (randomized, FOOD PRODUCT (EG JUICE) double-blind, placebo controlled studies ranging from • Lactobacillus plantarum 299v (DSM 9843) 40-200 subjects), achieved amongst others the following • Approx. 10 billion CFU/ daily dose at end of shelf-life strong clinical effects in the GI area: - dose 200-250ml • Shelf stability: Chilled drinks 35-75 days (8°C/4°C) LP299V® clinical studies have shown: • 100% reduction of abdominal pain SUPPLEMENT (EG CAPSULES) • 60% normalization of stool frequency • Lactobacillus plantarum 299v (DSM 9843) • 95% improvement in IBS symptoms • Approx. 10 billion CFU/ dose at end of shelf-life Of which: - dose 1 capsule/day • 45% of subjects experienced complete improvement Shelf stability: 18-24 months ambient • 50% of subjects experienced partial improvement • Significant reduction of bloating (and gas formation) • Significant reduction of pain • Significant improvement of overall GI functions • LARGE MARKET On average adults yearly suffer from 2 to 3 episodes of cold/flu and children from 6 to 10. CLINICAL EFFECTS Probi has, in three state-of-the-art designed clinical studies (randomized, double-blind, placebo controlled) on a total of 600 subjects, achieved the following clinical effects: FOOD PRODUCT (EG JUICE) • Lactobacillus plantarum HEAL9 (DSM 15312) and Lactobacillus paracasei 8700:2 (DSM 13434) • Approx. 1 billion CFU/ daily dose at end of shelf-life - dose 200-250ml • • Significant reduction of the incidence of common cold • Significant reduction of the number of sick days • Significant reduction of common cold symptoms • Stimulates the immune system Shelf stability: Chilled drinks 35-75 days (8°C/4°C) SUPPLEMENT (EG CHEWABLE TABLET) • Lactobacillus plantarum HEAL9 (DSM 15312) and Lactobacillus paracasei 8700:2 (DSM 13434) • Approx. 1 billion CFU/ dose at end of shelf-life - dose 1 tablet/day • Shelf stability: 18-24 months ambient PROBI – FIRST IN PROBIOTICS 9 HEALTH WORLD LIMITED, AUSTRALIA In January 2014, Health World Limited launched Inner Health Immune Booster for Adults, based on Probi Defendum®, on the Australian market. Health World, being Probi’s first partner in the Consumer Healthcare business, has successfully been selling Probi Digestis® for eight years in Australia and New Zealand. Graeme Joiner, Director of Sales & Marketing: “After years of successful sales and marketing of Probi Digestis®, we are happy to add a new probiotic concept from Probi, Probi Defendum®. In line with Probi’s proven R&D strategy the product has good and solid clinical documentation. We are looking forward to continue the close collaboration with Probi and take part in Probi’s growing probiotic pipline.” Health World is a leading supplier of natural medicines in Australia and New Zealand by providing high quality effective products based on the latest scientific research. Health World ensures product quality, safety and efficacy by strictly analyzing and testing their products on site at their purpose built manufacturing facility in Northgate, Queensland. BIO-LIFE, MALAYSIA In November 2013, BiO-LiFE launched PROBI LP299V®, based on Probi Digestis® on the Malaysian market. BiO-LiFE is a growing healthcare subsidiary within DKSH, the leading Market Expansion Service provider with a focus on Asia, giving the opportunity to expand in the region. John Goebel, General Manager “We are very pleased to partner with Probi, a leading company in probiotic research, for the launch and branding of PROBI LP299V® and bringing a clinically studied and unique product for the treatment of IBS related symptoms to the Malaysian market. We look forward to establishing the PROBI LP299V® brand in Malaysia.” BiO-LiFE Marketing is a growing healthcare subsidiary within DKSH, the leading Market Expansion Services provider with focus on Asia. The first BiO-LiFE branded products were launched in Malaysia in 1990. Since then, the brand has developed a wide range of quality and efficacious products, built on partnering with industry leaders for natural healthcare. 10 PROBI – FIRST IN PROBIOTICS PROBIOTIC FACTS No scientific studies exist that show any risks in conjunction with the consumption of lactobacilli. Lactic acid bacteria have been used for thousands of years for lactic fermentation of food. The method is a way of preserving food and is used all over the world. Most scientists agree that probiotic microorganisms used must fulfill certain requirements. To be called probiotic, these microorganisms should: 1. be safe 2. have a high rate of survival in the products in which they are used 3. have a high rate of survival in the gastrointestinal tract 4. be able to adhere to the intestinal mucosa 5. demonstrate clinically proven beneficial health effects SELECTED PRODUCTS 100% JUICE SHOT Bravo Friscus, launched in 2009, was a major research breakthrough. ProViva Shot is a more concentrated ProViva fruit drink that was It was one of the first 100% juices in the world to contain active bacteria launched in 2003. As the name implies, the product should be cultures. The unique formula of probiotic bacteria – Lactobacillus consumed in one shot a day. The concentration of bacteria is five plantarum HEAL 9 and Lactobacillus paracasei 8700:2, forming times higher than in the fruit drinks. ProViva Shot is a convenient way Probi Defendum – supports the body’s natural defences. Golden to start a new and healthy habit. ® Circle Healthy Life™ Fruit Juice with Probiotic Cultures, based on Probi Defendum®, is the first of its kind in Australia. PROVIVA50 ProViva50 contains 50% less sugar compared to juices and other fruit FRUIT DRINKS drinks. ProViva50 has no added sugar – the sugar comes from the The ProViva fruit drink, launched in 1994, is one of the most successful fruit’s natural sugar and a small amount of stevia has been added. probiotic food products in the world. Lactobacillus plantarum 299v has extensive clinical documentation in the gastro field. In November SHOT PLUS 2003, ProViva was the first probiotic product outside Japan to GoodBelly was launched in 2008 in the US by NextFoods. The drink receive official approval from an authoritative body (the Swedish is essentially the same as the ProViva drink sold in Scandinavia, but Nutrition Foundation) to be marketed with a product-specific health has a flavor profile and nutritional formula adapted to the US market. claim. ProViva, as well as GoodBelly fruit drinks, are based on Probi GoodBelly Plus is a probiotic fruit drink that in a single shot provides Digestis®. a large amount of essential nutrients with a high dose of Lactobacillus plantarum 299v. ACTIVE RECOVERY DRINK Clinical trials have shown that ProViva Active increases the body’s STRAIGHT SHOT antioxidative capacity, protecting the cells from free radicals formed GoodBelly StraightShot is a gently flavored dairy-free oatmilk with 20 in the body during physical exercise. The nutritional profile is adopted billion live and active probiotic cultures per serving, and no added to replenish energy levels and support recovery after sports. ProViva sugar. Active is based on Probi Digestis®, containing the Lactobacillus plantarum 299v strain. BIGSHOT 50 GoodBelly BigShot 50 contains 50 billion live probiotic bacteria SOUR MILK per shot and is targeted towards consumers with special needs or ProViva sourmilk has a unique creamy consistency and contains only experiencing digestive flare-ups. The product has a high concentration 0.5% fat. It has the same concentration of Lactobacillus plantarum of bacteria, but is sufficiently mild for daily consumption. 299v as the fruit drinks. 12 PROBI – FIRST IN PROBIOTICS PROBI’S PROBIOTIC APPLICATIONS • Fruit drinks • Soy • Fruit shots • Frozen Foods • Juices 100% • Ice Cream • Recovery drinks • Cereals • Yogurt • Bars • Drinking yogurt • Powdered Beverages • Kefir/Sour-milk • Delivery Solutions • Fresh Milk • Tablets • Cheese • Capsules • Fresh cheese • Sachets VEGGIE DRINK GoodBelly veggie drink offers a combination of carrots and ginger. Carrot Ginger is gluten-free and fortified with 20 billion live and active probiotic cultures per serving. COCONUT WATER GoodBelly fermented probiotic coconut water is made with a glutenfree, non-GMO oat flour. PROBIOTIC GASTRO/IBS CAPSULE Probi’s Gastro product is positioned against IBS (Irritable Bowel Syndrome) symptoms like abdominal pain, bloating, constipation, flatulence, etc. One example is Probi’s own brand, Probi Mage®. PROBIOTIC IMMUNE TABLET Probi has developed a probiotic chewable tablet to reduce negative effects associated with colds and flues. Until now no effective treatment to fight viruses has been available. One product example that fulfills this demand is Probi’s own brand, Probi Frisk®. READ MORE ABOUT: ProViva at proviva.com GoodBelly at goodbelly.com Probi Mage® and Probi Frisk® at bringwell.com* *Distributed and marketed by Bringwell. PROBI – FIRST IN PROBIOTICS 13 A PA R T N E R T H R O U G H O U T T H E P R O C E S S BENEFIT FROM A WELL-PROVEN PARTNER MODEL Probi develops and sells probiotics in two areas: Functional Food and Probi has a proven track-record with its long-term partner model Consumer Healthcare. designed to benefit both parties. In the area of Functional Food, probiotic concepts exist for a number Probi offers licenses and sell finished products to companies of ordinary foodstuffs, and new concepts are being developed that produce, distribute and sell functional foods and/or dietary continuously. supplements. Interest in foods with specific health-promoting characteristics over Probi grants licenses for its technology to food companies, usually in and above their nutritional value has increased markedly in recent the form of a royalty on the customers´ sales of products. In the case years. This increased demand has led major food manufacturers to of Consumer Healthcare, Probi usually sells finished goods in bulk. start establishing wide ranges of probiotic products. It is however Probi’s customers, according to their specific preference, then difficult for probiotics to survive in all types of food. Probi’s probiotics package these locally. This model guarantees high probiotic stability have both documented beneficial health effects and survive for an and minimizes time-to-market. extended period of time in a variety of foods, including fruit drinks, cereals and müsli bars. In some cases, Probi offers exclusivity to customers against special compensation, such as down payments. Probi’s probiotics are primarily used in chilled food products. Product categories that have been successfully enriched with Probi’s probiotics We offer our partners expertise in probiotic research and are juices, fruit drinks, yoghurt and ice cream, but also ambient development, and contribute in-depth competence in areas such products such as breakfast cereals and bars. Probi has a strong as science, product development, industrialization and regulatory position in technically difficult applications thanks to its robust and support as well as marketing. effective bacteria. DOCUMENTED BENEFICIAL HEALTH EFFECTS AND LONG SURVIVAL In the area of Consumer Healthcare, Probi offers solutions for all of the most common applications, including capsules and tablets. The demand for products that fall into the zone between traditional foods and pharmaceuticals is extensive. The common denominator for these products is their beneficial health effects. To obtain an optimal effect from probiotics, it is essential for a bacterium to survive the food manufacturing process, the product’s “At Probi, we support our customers with know-how to ensure shelf-life and yet colonize in the GI tract. A number of factors limit the and check the survival of probiotics during the manufacturing bacteria’s survival and product shelf-life: heat, water activity (for dry processes. This ensures that customers obtain the optimal effect applications) and the existence of antibacterial components in the of Probi’s probiotics in their products.” finished product. 14 PROBI – FIRST IN PROBIOTICS A ONE-STOP SHOP OFFER • Global market knowledge • Broad R&D expertise • Microbiology • Nutrition • Application and product developement • Medicine • Regulatory • Strong know-how in demanding applications PROBI R&D R&D – THE HEART OF PROBI The foundation and heart of Probi is research and development. That is why we can state that our probiotic bacteria are potent and have GUN-BRITT FRANSSON ON PROBI’S RESEARCH AND DEVELOPMENT STRATEGY a validated effect. ”The research strategy is based on Probi having a research As Probi was founded by microbiologists and surgeons, it is in the portfolio with both long and short-term projects and a company’s heart that the results rest on prominent basic and applied balanced level of risk. Recently, an inventory of new product research. This has affected Probi’s culture and work method during the areas was implemented to identify areas where Probi’s entire life time of the company – and so it will remain. probiotics are considered to provide health benefits and to have major commercial potential. Probi used the results to The R&D organization’s work is carried out in a similar way of that produce a clinical research programme for the coming years. of the pharmaceutical industry and the basic research is continuously This programme includes broadening the documentation for carried out at Lund University by a team funded by Probi. Further R&D is existing products to also include children. then performed by Probi and the pre-clinical and clinical development is continued under the full control of the company. Larger clinical trials In addition, Probi focuses on improving existing products and are often performed in cooperation with well-known CRO’s. At Probi, developing new product matrices.” we focus on specific health issues where probiotics have a positive impact and we also take the responsibility for product safety. Clinical and product development usually takes at least three years from concept to finished product. To ensure that the scientific results are turned into products, Probi has a dedicated product development department responsible for preparing external production of various products. Probi intends to continue being a pioneer in probiotics by launching new products addressing important health needs. We will achieve Gun-Britt Fransson this by increasing the pace of research and product development. Vice President Research & Development Probi is renowned throughout the industry for delivering clinical data of the highest quality through its international collaborations. Probi continuously focuses on gastro health and on the immune OVER A HUNDRED PATENTS WORLDWIDE system. Currently, active research is conducted within the following focus areas: Patents are very important, both for Probi’s scientific renown • Disorders of the stomach and gastrointestinal tract and for allowing commercialsation through licensing. Probi • The immune system has patents protecting its core probiotic strains and their health • The metabolic syndrome (including cardiovascular properties. The patent portfolio is monitored and analyzed disease, type 2 diabetes and obesity) regularly and Probi currently has over a hundred patents Stress and recovery (including nutrient uptake) worldwide. • 16 PROBI – FIRST IN PROBIOTICS OUR SUCCESSFUL IMMUNE STUDIES Probi’s successful common cold study in Berlin generated worldclass results. In 2009 the first product based on the research was launched. The product – a fruit juice called Bravo Friscus – contains a combination of two probiotic strains that regulate the immune system, resulting in reduced cold symptoms and shortened cold periods. The clinical findings surpass results from previous competitive studies. Cold symptoms among trial recipients of Probi’s product fell by 34 per cent compared with the placebo group. Also, the length of the cold periods were significantly reduced among people who received Probi’s product: (5.6 days as opposed to 6.7 days for the placebo group). In a previous study with the same combination of probiotic strains, it has been statistically proven that the strain combination reduces the risk of getting a cold as well as the number of days with cold symptoms. Probi’s product contains a combination of two probiotic strains, one Lactobacillus plantarum and one Lactobacillus paracasei. Probi has been unable to identify any current product on the world market that can match these results. This has provided Probi with the impetus and a chewable tablet was launched for the first time at the end of 2009 beginning of 2010 together with the Nordic health care company Bringwell. The successful clinical development has broadened Probi’s scope and opened up a new global market for Probi with an estimated value of about SEK 40 billion. I T S TA R T E D W I T H A V I S I O N T O S AV E L I V E S After a few days Bengt Jeppsson realised that he may have removed too much of his own intestine. As a surgical professor he should have known better, but the probiotics project – where he was the “guinea pig” – was so exciting that he got carried away….and that’s just the beginning of the Probi story. It all began when Surgery Professor Stig Bengmark observed the high frequency of infection among patients who had undergone large liver or pancreas operations. The most common postoperative treatment was to give patients large doses of antibiotics to prevent infection. Stig Bengmark’s idea was to strengthen the intestinal mucosa with a Bengt Jeppsson Göran Molin new and improved nutrient solution, thus preventing harmful intestinal bacteria from leaking into the rest of the body. This idea marked the in their intestines to see whether any probiotic candidates had start of a partnership with some of the other key people behind Probi. established themselves in their intestinal microflora. This led to a completely new type of nutrient solution with a probiotic The trials identified two strains of the Lactobacillus plantarum species bacterial strain that had been used to ferment an oat-based drink. Oats with beneficial properties and after further trials, an oat-based soup contain betaglucans and certain lipids, which could have been the fermented with the Lactobacillus plantarum 299v bacterium was properties that strengthened the intestinal wall, but the team gradually produced – which is the active bacterium today in Probi’s products for became more and more convinced that the key to strengthening the gastrointestinal health. mucosa lay in this newly discovered bacterial strain. Tests on both patients and healthy individuals demonstrated that the BACTERIA – FROM SUPPORTING ROLE TO LEADING PLAYER oat-based bacteria had obvious beneficial effects on intestinal health The difficulty lay in finding a nutrient solution that was similar to and general well-being. real food, contained a high degree of roughage and had the right consistency to pass through a thin tube. Stig Bengmark contacted The leading scientists in this project with the fermented probiotic drink food technologist Kåre Larsson, who was a prominent surface and were Professor Nils Molin, Göran Molin, Siv Ahrné and Clas Lönner. lipid chemist with an interest in grains – particularly oats. Oats were They remain partners to Probi today. already recognised as a suitable base for nutrient solutions. The idea of using bacteria came from a method of fermenting an oat-based FOOD OR DRUG? soup to make the mixture thinner. The greatest issue was whether the oat-based drink was a drug or something else. Probi was founded in 1991, but with no definitive Kåre Larsson thus brought together Stig Bengmark and Professor Nils decision regarding the company’s commercial focus. Molin, who worked with all forms of industrial fermentation processes. In 1992, after a contact with Skånemejerier’s development department ”This project contained interesting microbiological, food technological which luckily was positive, a joint project was initiated to investigate and medical features. We were lucky because resources and expertise the market potential. were available close by and everyone involved was enthusiastic,” says Kåre Larsson. Luck is one of the factors behind Probi – but there are at least two more factors behind the success; the passion and conviction behind Parallel to these trials with oats, an extensive study was carried out all of Probi’s research. to isolate the lactobacilli that were best suited to industrial processes, 18 and that could also adhere to, and survive in, the intestinal mucosa “Our collaboration between many fields of expertise such as after they were eaten. This also raised the question of what they could microbiologists, surgeons, marketing specialists and food technologists achieve – whether they had any beneficial health effects. has been totally unique,” says Clas Lönner. This was the reason why Bengt Jeppsson and a number of colleagues “This company has produced some excellent research. We’ve made swallowed the preparations containing various probiotic candidates. some wise and well-informed decisions along the way but also dared In the weeks that followed, biopsies were taken from various locations to take risks and test entirely new methods,” says Siv Ahrné. PROBI – FIRST IN PROBIOTICS C O N TA C T A N D M O R E I N F O R M AT I O N MARKETING & SALES – CONSUMER HEALTHCARE VISITING ADDRESS: Johan Wahlqvist, Director Marketing & Sales Sölvegatan 41A Phone: +46 46 286 89 27 Lund, Sweden E-mail: [email protected] POSTAL ADDRESS: Probi AB Ideon Gamma 1 223 70 Lund, Sweden MARKETING & SALES – FUNCTIONAL FOOD Ingvar Wirfelt , Director Marketing & Sales TELEPHONE: Phone: +46 46 286 89 65 +46 46 286 89 20 E-mail: [email protected] FAX: +46 46 286 89 28 E-MAIL: MARKETING & SALES – REGIONAL DIRECTOR EMEA [email protected] Michael Møller Jensen, Regional Director Marketing & Sales [email protected] Phone: +46 76 336 87 11 E-mail: [email protected] WEBSITE: www.probi.com RESEARCH AND DEVELOPMENT Niklas Larsson, PhD Research Director Phone +46 46 286 89 21 E-mail: [email protected] APPLICATION DEVELOPMENT AND PRODUCTION Kerstin Holmgren, Director Production & Application Development Phone +46 46 286 89 72 E-mail: [email protected] PROBI – FIRST IN PROBIOTICS 19 P O S TA L A D D R E S S : PROBI AB IDEON GAMMA 1 223 70 LUND, SWEDEN VISITING ADDRESS: S Ö LV E G ATA N 4 1 A LUND, SWEDEN TEL +46 46 286 89 20 FA X + 4 6 4 6 2 8 6 8 9 2 8 [email protected] W W W. P R O B I . C O M